CAJ | 학술논문

　　目的探讨新辅助化疗方案治疗三阴乳腺癌的疗效。方法选取2009年1月～2013年1月在我院接受治疗的三阴乳腺癌患者88例作为研究对象，随机分为对照组与观察组，对照组采用AC（阿霉素+环磷酰胺）新辅助化疗方案，观察组采用ET（蒽环类+多西紫杉醇）新辅助化疗方案，对比两组患者的疗效、肿瘤标志物CA15-3转阴的疗程数以及并发症情况。结果 AC与ET组的新辅助化疗有效率分别为54.8%及80.5%，对比具有统计学意义（χ2=9.386， P=0.025），肿瘤标志物CA15-3转阴的疗程对比χ2=5.427，P=0.019，具有统计学意义；不良反应较轻，经对症处理均能完成化疗疗程。结论新辅助化疗方案对三阴乳腺癌疗效肯定，但仍有一定的局限性，其中以蒽环类联合紫杉醇类效果较好。
　　목적탐토신보조화료방안치료삼음유선암적료효。방법선취2009년1월～2013년1월재아원접수치료적삼음유선암환자88례작위연구대상，수궤분위대조조여관찰조，대조조채용AC（아매소+배린선알）신보조화료방안，관찰조채용ET（은배류+다서자삼순）신보조화료방안，대비량조환자적료효、종류표지물CA15-3전음적료정수이급병발증정황。결과 AC여ET조적신보조화료유효솔분별위54.8%급80.5%，대비구유통계학의의（χ2=9.386， P=0.025），종류표지물CA15-3전음적료정대비χ2=5.427，P=0.019，구유통계학의의；불량반응교경，경대증처리균능완성화료료정。결론신보조화료방안대삼음유선암료효긍정，단잉유일정적국한성，기중이은배류연합자삼순류효과교호。
Objective To explore the efficacy of the neoadjuvant chemotherapy in the treatment of triple-negative breast cancer. Methods 88 patients with triplenegative breast cancer were chosen as research subjects from January 2009 to January 2013 in our hospital. The patients were randomly divided i nto control group and observation group, the control group were used AC(doxorubicin+cyclophosphamide) as treatment options, the observation group were used ET(anthracycline+docetaxel) as treatment options. The efficacy of patients in two groups, the number courses of tumor maker Ca15-3 negative, and com-plication were observed. Results The response rates of AC and ET group were 54.8% and 80.5%. There were significant differences between two groups,χ2=9.386,P=0.025. The negative number courses of tumor marker CA15-3 compared χ2=5.427, P=0.019, with statistical significance. All the patients completed the chemotherapy treatment after symptomatic treatment. Conclusion The neoadjuvant chemotherapy for TNBC was effective, but there were still some limitations, anthracy-clines and paclitaxel class group had better efficacy.